Company extends preclinical and clinical histopathology/molecular pathology solutions to researchers on both sides of the Atlantic
StageBio, a leading provider of GLP-compliant necropsy, histology, pathology and specimen archiving services for both preclinical and clinical research, announced its acquisition of TPL Path Labs of Freiburg, Germany. The combined organization offers an expanded array of histopathology, molecular pathology, toxicology, digital image analysis and related solutions to biopharma, medical device and academic researchers across the U.S., Europe and beyond. StageBio is a portfolio company of Ampersand Capital Partners.
The acquisition expands StageBio’s preclinical and clinical laboratory resources, adding a GLP/GCLP-compliant lab facility and staff in Germany to the company’s existing six GLP-compliant lab facilities and two GLP specimen archive sites in the U.S. This strengthens StageBio’s ability to deliver services internationally, reducing the need to ship study materials overseas. Uniform technology platforms and protocols across the U.S. and European operations ensure consistent quality, accuracy and efficiency.
Recommended AI News: Vyopta And Barco Overture Offer Integrated Room And Video Collaboration Monitoring Solution
With more than 175 professionals, including 30 experienced pathologists, the combined organization has the scale to serve the largest multinational customers, while retaining the highly responsive and personalized service for which StageBio is known.
Together, StageBio and TPL Path Labs offer an exceptionally broad array of solutions across the preclinical, translational and clinical continuum—from study protocol development through necropsy, histology, pathology, imaging and analysis. In particular, the acquisition enhances StageBio’s ability to support clinical investigators in the areas of biomarker development, tissue cross-reactivity (TCR) and immunohistochemistry.
Recommended AI News: Ivacy VPN & Startpage Collaborate To Strengthen Internet Users’ End-To-End Online Privacy Experience
“The addition of TPL Path Labs to StageBio represents a significant step in our global strategy to support researchers with the broadest range of quality solutions at every stage of discovery through clinical development,” said Tom Galati, StageBio CEO. “The expertise and sophisticated capabilities of the TPL team integrate perfectly with StageBio’s, enabling us to deliver solutions with a combination of depth, breadth and quality that is unmatched in the markets we serve.”
“Becoming part of StageBio is great news for TPL Path Labs’ customers across Europe, Australia and Asia,” said Ayse Bal, TPL Path Labs General Manager. “By expanding our capabilities, scale and geographic reach, the combined organization enables us to respond even more rapidly and effectively to our customers’ needs. StageBio shares our commitment to customer success and responsive service, making this an ideal match.”
Recommended AI News: ThinkIQ Digital Manufacturing Pioneer Raises $11.6 Million